Tesamorelin IGF-1 Monitoring Guide: Lab Schedule, Dose Adjustment & UAE 24h Delivery (2026)

Why IGF-1 Is The Single Most Important Marker

Tesamorelin is a stabilised growth-hormone-releasing hormone (GHRH) analogue. It binds the GHRH receptor in the anterior pituitary and triggers pulsatile GH release. GH itself has a half-life of 15-20 minutes, so measuring it directly is useless for monitoring — values bounce hour-to-hour. The downstream IGF-1, produced mainly in the liver in response to GH exposure, is stable over days and integrates GH activity into a single number.

That is why every pivotal tesamorelin trial — Falutz 2007, Stanley 2014, Spooner 2018 — used IGF-1 as the safety and efficacy biomarker. If you cannot measure IGF-1 in your research environment, you should not be running a tesamorelin protocol. It is the only practical guard against the chronically supraphysiological GH exposure that drives the long-term risks (insulin resistance, fluid retention, theoretical neoplasia risk).

Normal vs Supraphysiological IGF-1 — Age-Adjusted Ranges

IGF-1 falls steeply with age. A "normal" 200 ng/mL in a 60-year-old is solidly in the upper third; the same number in a 25-year-old is mid-range. Always use the lab's age-stratified reference, never a single cutoff. Typical adult ranges from the chemiluminescent immunoassays used at most UAE labs:

These are representative of the Siemens IMMULITE and Roche Cobas assays. Your specific UAE lab may use Beckman or DiaSorin, which produce ranges that differ by 10-15%. The principle holds: stay within the age-adjusted upper third, treat anything above the upper limit as a yellow card, anything above the concern threshold on confirmation as a red card.

The Monitoring Schedule That Works

Replicating the cadence used in Falutz 2007 and Stanley 2014:

Always draw IGF-1 in a consistent state: morning, fasted, before your weekly injection (not 12 hours after). IGF-1 itself is stable across the day but pre-analytical consistency removes one variable from longitudinal comparison.

When to Reduce the Tesamorelin Dose

Standard research dose in the Theratechnologies protocol was 2 mg subcutaneous daily. Many UAE research protocols start lower (1 mg daily) to confirm tolerability before escalating. Dose-reduction triggers are objective:

1. IGF-1 above the age-adjusted upper limit on two consecutive draws 4 weeks apart. Halve the dose. Recheck in 4 weeks.
2. IGF-1 above the concern threshold on a single draw. Repeat within 2 weeks. If confirmed, halve the dose immediately.
3. Any IGF-1 above 400 ng/mL regardless of age. Hold completely. Investigate for pituitary or hepatic anomaly before resuming.
4. Fasting glucose rise of more than 15 mg/dL from baseline. Reduce dose; the GH surge is impairing insulin sensitivity.
5. HbA1c rise of more than 0.3% from baseline within 24 weeks. Reduce dose and reassess metabolic baseline.
6. Persistent peripheral oedema or carpal tunnel symptoms. Classic GH excess sign — reduce dose by half.
7. Joint pain or arthralgia not present at baseline. Hold for 2 weeks; resume at half dose.

The asymmetry to remember: it is easy to halve the dose and re-measure 4 weeks later. It is much harder to walk back the consequences of sustained supraphysiological IGF-1 over months. Err toward conservative when in doubt.

UAE Lab Availability — Where to Run IGF-1

The IGF-1 panel is offered at every major UAE hospital chain and most diagnostic networks. Cost typically runs AED 180-340 per draw; turnaround 24-48 hours. Practical options:

• Mediclinic (Dubai, Abu Dhabi, Al Ain): Roche Cobas platform, 24h turnaround, age-stratified reference ranges printed on report.
• Aster Clinic & Aster Labs (all emirates): Siemens IMMULITE; in-network referral possible from any Aster GP appointment.
• NMC Royal & NMC Specialty (Dubai, Abu Dhabi, Sharjah): Beckman platform; rapid panel turnaround of 24h.
• Burjeel Medical City (Abu Dhabi): Tertiary endocrinology workup including IGF-BP3 if needed.
• Valiant Clinic (Dubai City Walk): Concierge draw with same-day-PM result for morning draws.
• Thumbay & University Hospital Sharjah: Northern Emirates coverage with home phlebotomy.
• RAK Hospital (Ras Al Khaimah): Routes samples to Dubai labs; report in 48-72h.

For longitudinal monitoring, always use the same lab and ideally the same platform. Inter-assay variability can move IGF-1 by 20-30%, which is the same magnitude as a real dose response — switching labs mid-protocol introduces noise that ruins your monitoring data.

UAE Delivery & Sourcing — Where to Buy Tesamorelin in the UAE with 24h Delivery

REVIVE Peptides operates from Dubai with cold-chain infrastructure built specifically for the UAE climate. Tesamorelin is shipped in insulated boxes with phase-change gel packs rated to maintain 2-8°C for 48 hours even in 45°C summer ambient conditions. Per-emirate delivery profile:

Stock status in Dubai is updated daily — tesamorelin 5 mg and 10 mg are kept at consistent depth as one of REVIVE's top-three SKUs. To buy tesamorelin UAE 24h delivery the ordering process is: select vial size, confirm cold-chain delivery slot, pay (card or bank transfer), receive HPLC certificate of analysis on dispatch confirmation. Reconstitution support and IGF-1 monitoring guidance available via the research desk.

For broader protocol context, see our UAE peptide catalogue for sibling sourcing (BAC water, syringes, complementary peptides such as GHK-Cu commonly co-stacked).

Common IGF-1 Mistakes That Ruin Research Data

• Drawing IGF-1 at varying times of day or fed state. IGF-1 is more stable than GH, but pre-analytical consistency still matters for longitudinal comparison.
• Switching labs mid-protocol. Inter-assay differences alone can move IGF-1 by 20-30%.
• Treating a single elevated value as a dose-adjust trigger. Always confirm with a repeat draw 2-4 weeks later before halving dose.
• Ignoring age-adjusted ranges. A 250 ng/mL value is benign in a 30-year-old, concerning in a 65-year-old.
• Skipping fasting glucose and HbA1c. IGF-1 alone misses the metabolic side of GH excess.
• Drawing IGF-1 before week 4. Pre-week-4 values do not reflect steady state — you will waste a draw.

Co-Monitoring Beyond IGF-1

IGF-1 is the headline marker but a complete tesamorelin monitoring panel adds:

• Fasting glucose & HbA1c — GH antagonises insulin; document baseline metabolic status.
• Lipid panel — tesamorelin reduces visceral adipose tissue (Falutz 2007); track triglycerides as efficacy proxy.
• Visceral fat measurement — CT or DEXA at baseline and 26 weeks if accessible; the Stanley 2014 endpoint.
• Resting heart rate & blood pressure — weekly home measurement, log for trend.
• Body composition (DEXA) — every 12 weeks if available; tesamorelin's effect is fat redistribution, not weight loss per se.

For protocol context on stacking and timing, see our tesamorelin vs CJC-1295 comparison and the broader GHRH vs GHRP research overview.